How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

65,172 results for

Type 1 Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. (PubMed)

Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. The use of short-acting insulin analogues (insulin lispro, insulin aspart, insulin glulisine) for adult, non-pregnant people with type 2 diabetes is still controversial, as reflected in many scientific debates.To assess the effects of short-acting insulin analogues compared to regular human insulin in adult, non-pregnant people with type 2 diabetes mellitus.For this update (...) we searched CENTRAL, MEDLINE, Embase, the WHO ICTRP Search Portal, and ClinicalTrials.gov to 31 October 2018. We placed no restrictions on the language of publication.We included all randomised controlled trials with an intervention duration of at least 24 weeks that compared short-acting insulin analogues to regular human insulin in the treatment of people with type 2 diabetes, who were not pregnant.Two review authors independently extracted data and assessed the risk of bias. We assessed

2018 Cochrane

42. A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial

A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404 (...) Realf 4 , Timothy Skinner 6 , Bernie Stribling 4 , Jacqui Troughton 4 , Thomas Yates 1 , Kamlesh Khunti 1 1 Diabetes Research Centre, University of Leicester, Leicester, UK 2 Department of Health Sciences, University of Leicester, Leicester, UK 3 Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK 4 Leicester Diabetes Centre, University Hospitals of Leicester, Leicester, UK 5 Patient and Public Involvement Group, Leicester Diabetes Centre

2017 NIHR HTA programme

43. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

inhibitors, SGLT-2 inhibitors, and SGLT-1/SGLT-2 inhibitors may be considered experimental drugs being tested for adjunctive therapy in T1D adult patients. As such, their place in therapy in the management of T1D still needs to be defined. Background Diabetes mellitus is a metabolic disorder that results from defects in insulin secretion, insulin action, or both. 1 There are two major categories of diabetes. Type 1 diabetes (T1D) is characterized by severe impairment or an absolute deficiency of insulin (...) Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? | CADTH.ca CADTH Document Viewer Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Table of Contents Search this document Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? January 2018 Summary There are two major

2018 CADTH - Issues in Emerging Health Technologies

44. Illness perception of adolescents with well-controlled type 1 diabetes mellitus (PubMed)

Illness perception of adolescents with well-controlled type 1 diabetes mellitus In this study, to explore the illness perceptions of adolescents with well-controlled type 1 diabetes mellitus in South Africa, semi-structured interviews were conducted with nine, purposively selected adolescents (mean = 13.9 years; median = 12). Themes that emerged from the thematic analysis include the following: accepting diabetes and the diabetes care plan as part of their lives; viewing diabetes as manageable (...) and as their responsibility; and the important role of gaining information on diabetes and diabetes management. These perceptions contributed to adherence to diabetes care plans and should be explored and developed among adolescents with type 1 diabetes mellitus to improve their diabetes management.

Full Text available with Trip Pro

2018 Health psychology open

45. Minimed 670g - for the management of type 1 diabetes mellitus

Minimed 670g - for the management of type 1 diabetes mellitus Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for the is located below. Updated: The following (...) table describes post-licensing activity for the . For more information on the type of information found in PLATs, please refer to the For additional information about the medical device application process, refer to the . Licence Number: Post-Licensing Activity Table (PLAT) Activity/Application Type, Application Number Date Submitted Decision and Date Summary of Activities 1 What was approved? Application Milestones: Application Milestone Date For additional information about the medical device

2019 Health Canada - Drug and Health Product Register

46. Health-related quality of life in paediatric patients with Type 1 diabetes mellitus using insulin infusion systems. A systematic review and meta-analysis. (PubMed)

Health-related quality of life in paediatric patients with Type 1 diabetes mellitus using insulin infusion systems. A systematic review and meta-analysis. In 2017, more than 1.1 million children were living with type 1 diabetes mellitus (T1DM) globally. The goal in paediatric diabetes therapy is reaching optimal glycaemic control as early as possible in order to avoid complications and early mortality without compromising the quality of life (QoL) of children. Several different insulin regimens (...) are available for T1DM patients to reach this goal.This review set out to analyse whether continuous subcutaneous insulin infusion (CSII) regimens are superior to multiple daily injection (MDI) therapy in T1DM youth regarding QoL. Additionally, it assessed glycaemic control and adverse events as secondary outcomes and discussed potential future public health implications and justifications for using CSII as a first-line therapy in diabetic youth.A systematic review and random effects meta-analysis

2019 PLoS ONE

47. Pre-conception care for women with type 1 or type 2 diabetes: A mixed methods study exploring uptake of pre-conception care

to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Preconception care for women with type 1 or type 2 diabetes mellitus: a mixed-methods study exploring uptake of preconception care {{author}} {{($index , , , , , & . Sarah Earle 1, * , Anisah Tariq 1 , Carol Komaromy 1 , Cathy E Lloyd 1 , M Ali Karamat 2 , Jackie Webb 2 , Paramjit S Gill 3 1 Faculty of Health and Social Care, The Open University, Milton Keynes, UK 2 (...) Pre-conception care for women with type 1 or type 2 diabetes: A mixed methods study exploring uptake of pre-conception care Pre-conception care for women with type 1 or type 2 diabetes: A mixed methods study exploring uptake of pre-conception care Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above

2017 NIHR HTA programme

48. Maternal Gestational Diabetes Mellitus, Type 1 Diabetes, and Type 2 Diabetes During Pregnancy and Risk of ADHD in Offspring. (PubMed)

Maternal Gestational Diabetes Mellitus, Type 1 Diabetes, and Type 2 Diabetes During Pregnancy and Risk of ADHD in Offspring. To examine the relative importance of maternal preexisting type 1 diabetes (T1D), preexisting type 2 diabetes (T2D), and gestational diabetes mellitus (GDM) on risk of attention deficit/hyperactivity disorder (ADHD) in offspring.This retrospective birth cohort study included 333,182 singletons born in 1995-2012 within Kaiser Permanente Southern California hospitals (...) . Children were prospectively followed through electronic medical records from age 4 years. Relative risks of ADHD associated with diabetes exposures in utero were estimated by hazard ratios (HRs) using Cox regression with adjustment for potential confounders. For GDM, timing of exposure was evaluated by gestational age at diagnosis and severity was assessed by the need for antidiabetes medication treatment during pregnancy.A total of 37,878 (11.4%) children were exposed to diabetes (522 exposed to T1D

2018 Diabetes Care

49. Empaglifozin linagliptin fixed-dose combination (Glyxambi) - type 2 diabetes mellitus:

Empaglifozin linagliptin fixed-dose combination (Glyxambi) - type 2 diabetes mellitus: Published 12 August 2019 1 Product Update: empagliflozin plus linagliptin 10mg/5mg, 25mg/5mg film-coated tablets (Glyxambi ® ) SMC No. (1236/17) Boehringer Ingelheim Ltd. 07 April 2017 (Issued July 2019) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission empagliflozin/linagliptin (Glyxambi ® ) is accepted for restricted use within NHS Scotland. Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus: ? To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi ® do not provide adequate glycaemic control ? When already being treated with the free combination of empagliflozin and linagliptin SMC

2019 Scottish Medicines Consortium

50. Pharmacotherapy Management of Type 2 Diabetes Mellitus: Guidelines

Pharmacotherapy Management of Type 2 Diabetes Mellitus: Guidelines Pharmacotherapy Management of Type 2 Diabetes Mellitus: Guidelines | CADTH.ca Find the information you need Pharmacotherapy Management of Type 2 Diabetes Mellitus: Guidelines Pharmacotherapy Management of Type 2 Diabetes Mellitus: Guidelines Last updated: December 12, 2018 Project Number: RA0993-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What are the evidence-based guidelines (...) regarding the optimal pharmacological management of Type 2 Diabetes Mellitus? Key Message Thirteen evidence-based guidelines were identified regarding the optimal pharmacological management of Type 2 Diabetes Mellitus. Files Rapid Response Reference List Published : December 12, 2018 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

51. Soliqua - lixisenatide + insulin glargine - Diabetes mellitus, Type 2

Soliqua - lixisenatide + insulin glargine - Diabetes mellitus, Type 2 lixisenatide + insulin glargine | CADTH.ca Find the information you need lixisenatide + insulin glargine lixisenatide + insulin glargine Last Updated: January 3, 2019 Result type: Reports Project Number: SR0564-000 Product Line: Generic Name: lixisenatide + insulin glargine Brand Name: Soliqua Manufacturer: sanofi-aventis Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria 1 (...) : Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medicinal products combined with basal insulin, or basal insulin alone do not provide adequate glycaemic control. Submission Type: New Combination Project Status: Complete Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: December 24, 2018 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

52. Steglatro - ertugliflozin - Diabetes mellitus, Type 2

Steglatro - ertugliflozin - Diabetes mellitus, Type 2 ertugliflozin | CADTH.ca Find the information you need ertugliflozin ertugliflozin Last Updated: January 25, 2019 Result type: Reports Project Number: SR0565-000 Product Line: Generic Name: ertugliflozin Brand Name: Steglatro Manufacturer: Merck Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria 1 : As monotherapy for patients who have inadequate glycemic control and for whom metformin (...) or a sulfonylurea is inappropriate due to contraindications or intolerance. Add-on to metformin for patients who have inadequate glycemic control on metformin and have a contraindication or intolerance to a sulfonylurea. Submission Type: New Project Status: Complete Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: January 23, 2019 Recommendation Type: Do not reimburse Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

53. Segluromet - ertugliflozin and metformin hydrochloride - Diabetes mellitus, Type 2

Segluromet - ertugliflozin and metformin hydrochloride - Diabetes mellitus, Type 2 ertugliflozin and metformin | CADTH.ca Find the information you need ertugliflozin and metformin ertugliflozin and metformin Last Updated: January 25, 2019 Result type: Reports Project Number: SR0566-000 Product Line: Generic Name: ertugliflozin and metformin hydrochloride Brand Name: Segluromet Manufacturer: Merck Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria 1 (...) : Added on to metformin for patients who have inadequate glycemic control on metformin and have a contraindication or intolerance to a sulfonylurea, or To replace the individual components of ertugliflozin and metformin for those patients who are on both therapies Submission Type: New Combination Project Status: Complete Biosimilar: No Companion Diagnostics: No Date Recommendation Issued: January 23, 2019 Recommendation Type: Do not reimburse Fee Schedule: Schedule C The requested reimbursement

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

54. Ozempic - semaglutide - Diabetes mellitus, type 2

Ozempic - semaglutide - Diabetes mellitus, type 2 semaglutide | CADTH.ca Find the information you need semaglutide semaglutide Last Updated: June 18, 2019 Result type: Reports Project Number: SR0594-000 Product Line: Generic Name: semaglutide Brand Name: Ozempic Manufacturer: Novo Nordisk Canada Inc. Indications: Diabetes mellitus, type 2 Manufacturer Requested Reimbursement Criteria 1 : For the treatment of adults patients with type 2 diabetes to improve glycemic control, in combination (...) with metformin (second line treatment) and in combination with metformin and sulfonylurea (third line treatment). Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: May 15, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

55. Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2

the Fridericia formula R AC Accumulation ratio RH relative humidity RQ (Environmental) Risk Quotient SBP systolic blood pressure SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics TAMC total aerobic microbial count TYMC total combined yeasts/moulds count T2DM type 2 diabetes mellitus t max time to C max UGE urinary glucose excretion UGT uridine 5’-diphospho-glucuronosyltransferase ULN upper limit of normal UV ultraviolet UV-Vis ultraviolet (...) Ertugliflozin is an oral, selective inhibitor of sodium glucose co-transporter-2 (SGLT2) which inhibits renal glucose reabsorption and results in urinary glucose excretion (UGE) and reductions in plasma glucose and haemoglobin A1c (A1C) in patients with type 2 diabetes mellitus (T2DM). It possesses a high selectivity for SGLT2 versus SGLT1 and other glucose transporters (GLUT1-4). Ertugliflozin is a new chemical entity with a chemical name of (1S,2S,3S,4R,5S)-5-[4-Chloro-3- (4- ethoxybenzyl)phenyl]-1

2018 European Medicines Agency - EPARs

56. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

analysis plan SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics SMQ Standard MedDRA Query SOC System organ class T2DM type 2 diabetes mellitus TAMC total aerobic microbial count Tmax time to first occurrence of maximum observed concentration TYMC total combined yeasts/moulds count UGE urinary glucose excretion ULN upper limit of normal US United States USPI United States Prescribing Information UTI urinary tract infection UV ultraviolet (...) , decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin is approved for use in the US, Europe, and other countries and has an established safety and tolerability profile. Type of Application and aspects on development The development program has in all essentials followed the EMA Guideline “Clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus” (CHMP/EWP/1080/00 Rev. 1

2018 European Medicines Agency - EPARs

57. Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2

in the circulation in a glucose-dependent manner. Type of Application and aspects on development The development program has in all essentials followed the EMA Guideline “Clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus” (CHMP/EWP/1080/00 Rev. 1), the EMA guideline “Clinical development of fixed combination medicinal products” (CHMP/EWP/240/95 Rev. 1) and the scientific advice given on the following topics: Design of non-clinical and clinical phase 3 development (...) Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86941/2018 Committee for Medicinal Products

2018 European Medicines Agency - EPARs

58. Dapagliflozin with insulin for treating type 1 diabetes

of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 242 2 Information about dapagliflozin Information about dapagliflozin Mark Marketing eting authorisation authorisation Dapagliflozin (Forxiga, AstraZeneca) is indicated for the treatment of 'type 1 diabetes mellitus as an adjunct to insulin in patients with a BMI = 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy' . Dapagliflozin should not be started in people (...) Dapagliflozin with insulin for treating type 1 diabetes Dapagliflozin with insulin for treating Dapagliflozin with insulin for treating type 1 diabetes type 1 diabetes T echnology appraisal guidance Published: 28 August 2019 www.nice.org.uk/guidance/ta597 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

59. Prevalence and characteristics of celiac disease in South African patients with type 1 diabetes mellitus: Results from the Durban Diabetes and Celiac Disease Study. (PubMed)

Prevalence and characteristics of celiac disease in South African patients with type 1 diabetes mellitus: Results from the Durban Diabetes and Celiac Disease Study. The aim of this study was to assess the prevalence and characteristics of celiac disease (CD) in all patients with type 1 diabetes mellitus attending a tertiary adult diabetes clinic in Durban, South Africa.This was a cross-sectional observational study that screened 202 patients; of these, 56.4% were African (Black), 31.7% Asian (...) from western countries. No ethnic specific differences were noted. CD was silent in all patients in this study. The sensitivity of EMA and tTG antibodies was poor and merits further evaluation as screening tools for CD in South African patients with type 1 diabetes mellitus.© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

2019 Journal of gastroenterology and hepatology

60. Changes in Retinal Microcirculation Precede the Clinical Onset of Diabetic Retinopathy in Children with Type 1 Diabetes Mellitus. (PubMed)

Changes in Retinal Microcirculation Precede the Clinical Onset of Diabetic Retinopathy in Children with Type 1 Diabetes Mellitus. To investigate whether abnormal glucose metabolism in diabetes mellitus (DM) affects the retinal microcirculation of children with well-controlled type 1 DM and to compare these results with those obtained from healthy children.Cross-sectional prospective study.This study enrolled 60 patients with DM without clinically detectable diabetic retinopathy (DR) and who met (...) and glycated hemoglobin (HbA1c) levels were evaluated among patients with type 1 DM.Differences in the mean values for FAZ perimeter, AI, and FD-300 were statistically significant between DM group and control group (P<0.001, P=0.001 and P=0.009, respectively). There were also statistically significant differences between the groups for vessel densities of deep superior hemi-parafovea, deep temporal parafovea, and deep superior parafoveal zones (P=0.008, P=0.015 and P=0.005, respectively). There were

2019 American Journal of Ophthalmology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>